The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Edward Hamilton Nash - Canaccord Genuity Corp., Research Division - Analyst
: First question I had, just a quick housekeeping one, is just with regards to not going any further on the COVID-19 development. I assume that we
won't see any more expenses or anything after this quarter -- or the first quarter. There won't be anything coming in the second quarter that's
meaningful?
Question: Edward Hamilton Nash - Canaccord Genuity Corp., Research Division - Analyst
: Okay. Great. And then my second question is kind of 2 parts related is with regard to the slow enrollment you're seeing with ENHANCE, is that
across -- rather than saying sites, let's say, territories. Is that pretty much across all territories equally? Or is there one that tends to lag more? I know
it's been kind of a whack-a-mole with COVID seeming to be taken care of and then resurgences constantly. So that's my first question.
And the second part of that is, is this issue with patient compliance and being lost to follow-up. And given COVID, this could obviously result in
maybe an increased number of patients more than we'd normally see, they're lost to follow-up. How is that being incorporated into the overall
powering of the trial?
Question: Edward Hamilton Nash - Canaccord Genuity Corp., Research Division - Analyst
: Great. And just -- I'm sorry, just one more thing, if I could, just related to that, is just with regard to the -- any protocol violations, clearly with COVID,
there's probably some -- you have to be a little bit flexible, but obviously, not in any way jeopardize the protocols of the trial itself, but has there
to date, I guess, been enough flexibility to kind of avoid protocol violations based on what centers have had to do with COVID?
|
